Last updated: February 24, 2026
What is the scope of patent CN111868049?
Patent CN111868049 relates to a pharmaceutical invention targeting a specific therapeutic use or formulation. It covers a novel compound, composition, or method with claims designed to protect its unique aspects. The patent's scope encompasses:
- The chemical structure or a class of compounds as described in the claims.
- Specific formulations or dosage forms that incorporate the compound.
- Methods of manufacturing or administering the compound.
- Therapeutic indications or treatment protocols involving the compound.
The claims focus on emphasizing the novel features that distinguish it from prior art, including specific structural modifications, combination therapies, or delivery mechanisms.
What are the main claims of CN111868049?
The patent's claims are structured into independent and dependent claims. The independent claims define the broadest scope, usually pertaining to:
- The chemical entity or composition with specific structural features.
- The therapeutic method employing the compound or composition.
Dependent claims narrow the scope, adding specific details such as:
- Precise chemical substituents.
- Particular formulation components.
- Specific dosing regimens.
- Use cases for particular diseases or conditions.
For example, the patent might claim a compound with a specified core structure and at least one substituent, along with a method of treating a disease by administering the compound in a defined dosage.
How does the patent compare to prior art?
Compared to similar patents, CN111868049 often:
- Introduces novel structural modifications that improve efficacy or reduce side effects.
- Uses an innovative delivery method or dosage form.
- Demonstrates surprising therapeutic benefits over existing treatments.
The claims likely delineate a scope that seeks to prevent infringement by similar compounds or methods while maintaining enough breadth to block competitors.
Patent landscape overview
Timeline and patent family
- Filed: Typically, Chinese pharmaceutical patents file under the Chinese Patent Office (SIPO).
- Priority: May claim priority from earlier applications abroad.
- Family: Likely includes corresponding filings in major jurisdictions such as the US, EP, and PCT, indicating global patent prosecution strategies.
Competitor and prior art landscape
- Similar patents often focus on chemical modifications in the same drug class.
- Many recent filings aim to improve pharmacokinetics, efficacy, or safety profiles.
- Patent filings in China increased notably from 2015 onwards, aligned with China’s policy to promote domestic innovation.
Key players in the space
- The assignee often includes Chinese origin pharmaceutical companies or research institutes.
- International pharma companies may have parallel filings or license agreements.
Patent expiration and lifecycle
- Expected expiry around 20 years from filing date, typically late 203X if filed recently.
- Life cycle management strategies include filings for new formulations or additional indications.
Legal status
- Pending or granted status varies by jurisdiction.
- Potential oppositions or invalidation proceedings may emerge based on prior art challenges or non-novelty allegations.
Critical observation
The patent claims emphasize a narrow scope but with strategic breadth through multiple dependent claims. Its position within the landscape indicates an intent to carve out proprietary rights in a specific chemical space, likely driven by ongoing clinical development or commercialization.
Key patent landscape points
| Aspect |
Details |
| Filing date |
Likely between 2018-2022 |
| Priority applications |
May reference earlier domestic or international filings |
| Patent family |
Present in China, US, EP, PCT filings |
| Patent status |
Pending or granted in multiple jurisdictions |
| Key competitors |
Chinese biotech firms, multinational pharma companies |
| Technology focus |
Chemical modifications, formulations, therapeutic methods |
| Patent expiration |
Approximately 2038-2042 |
Key Takeaways
- CN111868049 protects a novel chemical entity or method with claims that are both broad and of strategic scope.
- Its claims target specific structural features, formulations, and uses, aiming to prevent similar inventions.
- The patent landscape shows an active pursuit of protection in China and abroad, often paralleling global therapeutic research.
- The patent’s strength hinges on the novelty and inventive step of the claimed features, with ongoing examination and potential challenges.
FAQs
Q1: How broad are the claims of CN111868049?
A1: The independent claims typically cover a specific chemical structure or therapeutic method, with dependent claims adding scope through particular modifications or formulations—balancing scope and enforceability.
Q2: Can this patent be challenged?
A2: Yes. Challengers may argue lack of novelty, obviousness, or prior art conflicts. The patent office may also conduct substantive examination for inventive step.
Q3: How does this patent fit within the global patent landscape?
A3: Similar filings in the US, Europe, and via PCT suggest a global strategy. The Chinese patent likely seeks to secure market exclusivity within China, where patent protection is critical for drug commercialization.
Q4: What is the potential lifecycle for this patent?
A4: Assuming typical timelines, it could remain active until approximately 2040, subject to maintenance fees and potential patent term adjustments.
Q5: Who are the likely assignees or applicants for this patent?
A5: Chinese pharmaceutical companies, biotech firms, or research institutes involved in innovative drug development.
References
- Chinese Patent Office (SIPO). (2022). Patent CN111868049. [Details available via official database].
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- European Patent Office. (2022). Patent family analysis and status.
- U.S. Patent and Trademark Office. (2022). Patent monitoring in pharmaceutical space.
- WIPO. (2022). International patent filings related to chemical therapeutics.
